September 10, 2025European Heart Journal Supplements

Clinical outcomes of half-dose extended anticoagulation in cancer-associated pulmonary thromboembolism: a real-world cohort study

View Full Paper

Ask AI

Bookmark

Authors

MBMinjung BakSeoul National University Bundang Hospital JKJin Woo KimYonsei University HSHee Young ShinSeoul National University Children's Hospital

Discussion

Member takes

Implication

Real-world cohort study finds half-dose anticoagulation has similar effects on recurrence and bleeding in cancer patients with pulmonary thromboembolism.

Key Points

Extended anticoagulation with half-dose reduces the risk of recurrent PE/DVT without increasing bleeding.
Over a median follow-up of 33.4 months, 20.2% of patients had recurrent PE/DVT despite treatment.
Multivariate analysis shows advanced cancer status and impaired renal function contribute to higher recurrence risk.
Future trials are necessary to refine anticoagulation strategies and identify patient-specific risks in CAPE.

Cite This Study

Bak et al. (2025) studied this question.

synapsesocial.com/papers/68c23ed7b210217d64793a34 https://doi.org/10.1093/eurheartjsupp/suaf083.155

View Full Paper

Ask AI

Bookmark

Implication

Real-world cohort study finds half-dose anticoagulation has similar effects on recurrence and bleeding in cancer patients with pulmonary thromboembolism.

Clinical outcomes of half-dose extended anticoagulation in cancer-associated pulmonary thromboembolism: a real-world cohort study

Discussion

Member takes

Implication

Key Points

Cite This Study

Clinical outcomes of half-dose extended anticoagulation in cancer-associated pulmonary thromboembolism: a real-world cohort study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider